The Coming Peptide Free-for-All In the early 1990s, a grassroots movement in the United States successfully lobbied Congress to shield dietary supplements from the stringent regulatory oversight applied to pharmaceuticals. This campaign, largely driven by the vitamin industry, culminated in the 1994 Dietary Supplement and Health Education Act, which exempted supplement manufacturers from proving the safety and efficacy of their products through clinical trials. The law allowed companies to market supplements with minimal oversight, leading to an explosion in the industry’s growth. Today, the market is valued at over $70 billion, encompassing both evidence-backed products and numerous unproven, sometimes hazardous items. These include supplements marketed for boosting metabolism, muscle growth, and cognitive function, many of which lack rigorous scientific validation. Studies have linked these products to thousands of emergency department visits annually and a significant portion of liver injuries, highlighting the risks consumers face when purchasing unregulated health products. Now, a similar regulatory shift is emerging with experimental peptides—short chains of amino acids with potential therapeutic applications. These substances, often marketed as performance-enhancing or health-boosting agents, are gaining traction in a market that mirrors the supplement industry’s unregulated landscape. Unlike pharmaceuticals, which require extensive clinical trials to demonstrate safety and effectiveness, peptides are being pushed to bypass traditional FDA review processes. This trend is part of a broader effort to expand access to a range of drugs and ingredients that do not meet the agency’s standard evidence requirements.#fda #robert_f_kennedy_jr #dietary_supplement_and_health_education_act #peptides #wild_west
